Italfarmaco Presents New Cardiac Data for Givinostat
Italfarmaco presented new cardiac data for givinostat, its histone deacetylase (HDAC) inhibitor, at the 2025 European Paediatric Neurology Society...
Setmelanotide & Bivamelagon Data at ENDO 2025
Rhythm Pharmaceuticals presented data from its clinical programs for acquired hypothalamic obesity at the Endocrine Society’s Annual Meeting (ENDO...
KIF18A Therapies: FDA & EMA Approvals, Trials, and Indications
KIF18A, a mitotic kinesin motor protein overexpressed in cancers like ovarian and triple-negative breast cancers, is emerging as a...
Palsonify™ Demonstrates Durable Acromegaly Control in Long-Term Data
Crinetics Pharmaceuticals released new clinical data on its oral acromegaly drug, paltusotine (PALSONIFY), at ENDO 2025. The data, from...
Longeveron Announces FDA Approval of IND Application for Phase 2
Longeveron Inc. received FDA approval for its Investigational New Drug (IND) application for laromestrocel, a stem cell therapycell therapy...
Respect-LM Dose Optimization Trial Shows Success in Treating Leptomeningeal Metastases
Plus Therapeutics has begun treating the first patients in its ReSPECT-LM dose optimization trial for REYOBIQ™, a targeted radiotherapeutic...
Ultragenyx, Mereo Biopharma UX143 Orbit Study Final Analysis
Ultragenyx and Mereo BioPharma announced that the Phase 3 Orbit study of setrusumab for osteogenesis imperfecta (OI) in pediatric...
Tonix Publishes Phase 3 Fibromyalgia Trial Results of TNX-102 SL
Tonix Pharmaceuticals announced positive Phase 3 RESILIENT trial results for TNX-102 SL (sublingual cyclobenzaprine HCl tablets) in managing fibromyalgia...
Sil204 Shows Efficacy in Human Lung Cancer Cell Lines
Silexion Therapeutics (NASDAQ: SLXN) announced positive preclinical data for SIL204, its RNA interference (RNAi) therapy, in human lung cancer...
Seclidemstat’s Role in LSD1 Inhibition Validated in Oncology Studies
Salarius Pharmaceuticals announced positive preclinical data on its LSD1 inhibitor, seclidemstat, and provided an update on its merger with...